|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.92 USD | +19.67% |
|
+109.94% | +61.06% |
| 07-09 | Forte Biosciences, Inc. - Special Call | |
| 07-09 | Top Midday Gainers | MT |
Company Valuation: Forte Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,073 | - | - |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 120.71% | - | - |
| Enterprise Value (EV) | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,073 | 1,073 | 1,073 |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 120.71% | 0% | 0% |
| P/E | -1.38x | -1.25x | - | -1.87x | -5.79x | -10.7x | -10.3x | -10x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | - | - | 0.1x | 0.8x | -2.9x | -3.5x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | -0x | -0x | -11x | -8.22x | -6.83x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -38.75 | -20 | - | -12.17 | -4.71 | -4.106 | -4.252 | -4.373 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -36.6 | -70.66 | -97.38 | -130.5 | -157.2 |
| Net income 1 | -21.71 | -13.88 | - | -35.48 | -69.38 | -95.54 | -130.4 | -155.7 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 53.50 | 25.00 | 20.54 | 22.71 | 27.27 | 43.92 | 43.92 | 43.92 |
| Nbr of stocks (in thousands) | 590 | 840 | 1,453 | 6,393 | 17,831 | 24,436 | - | - |
| Announcement Date | 3/31/22 | 3/31/23 | 3/18/24 | 3/28/25 | 3/31/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.7x | - | - | - | 1.07B | |
| 20.57x | 6.33x | 13.8x | 1.56% | 54.88B | |
| 32.72x | 8.29x | 25.68x | 0.06% | 54.63B | |
| -44.31x | 14.51x | -42.32x | -.--% | 25.06B | |
| -18.2x | 4.33x | -7.58x | -.--% | 23.14B | |
| 25x | 4.9x | 12.9x | -.--% | 19.87B | |
| 24.48x | 4.79x | 15.58x | -.--% | 17.55B | |
| 49.34x | 20.07x | 51.69x | 0.07% | 16.5B | |
| -539.24x | 37.99x | -4235.53x | -.--% | 15.75B | |
| 17.75x | 5.16x | 12.01x | -.--% | 14.2B | |
| Average | -44.26x | 11.82x | -461.53x | 0.19% | 24.26B | |
| Weighted average by Cap. | -21.12x | 10.13x | -265.84x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBRX Stock
- Valuation Forte Biosciences, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
